Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 May 1;90(5):845-852.
doi: 10.1097/TA.0000000000003088.

Temporal profile of the pro- and anti-inflammatory responses to severe hemorrhage in patients with venous thromboembolism: Findings from the PROPPR trial

Belinda H McCully  1 , Charlie E Wade, Erin E Fox, Kenji Inaba, Mitchell J Cohen, John B Holcomb, Martin A Schreiber; PROPPR study group
Affiliations
Clinical Trial

Temporal profile of the pro- and anti-inflammatory responses to severe hemorrhage in patients with venous thromboembolism: Findings from the PROPPR trial

Belinda H McCully et al. J Trauma Acute Care Surg. .

Abstract

Background: The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial showed that 15% of patients developed venous thromboembolism (VTE) following hemorrhage, but the mechanisms are unknown. Since inflammation is associated with hypercoagulability and thrombosis, our goal was to compare the temporal inflammatory profile following hemorrhagic shock in patients with and without VTE.

Study design: Secondary analysis was performed on data collected from PROPPR. Blood samples collected at 0 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours following admission were assayed on a 27-target cytokine panel, and compared between VTE (n = 83) and non-VTE (n = 475) patients. p < 0.05 indicated significance.

Results: Over time, both groups exhibited elevations in proinflammatory mediators interleukin (IL)-6, IL-8, IL-10, granulocyte colony-stimulating factor 57, monocyte chemoattractant protein 1 and macrophage inflammatory protein 1β, and anti-inflammatory mediators IL-1ra and IL-10 (p < 0.05 vs. admission). Venous thromboembolism patients showed amplified responses for IL-6 (6-72 hours) and IL-8 (6-24 hours), which peaked at later time points, and granulocyte colony-stimulating factor 57 (12-24 hours), monocyte chemoattractant protein 1 (6-72 hours), and macrophage inflammatory protein-1 β (2-12 hours) (p < 0.05 vs. non-VTE per time point) that peaked at similar time points to non-VTE patients. The anti-inflammatory responses were similar between groups, but the interleukin-mediated proinflammatory responses continued to rise after the peak anti-inflammatory response in the VTE group. The occurrence rate of adverse events was higher in VTE (97%) versus non-VTE (87%, p = 0.009) and was associated with higher inflammation.

Conclusion: Patients with VTE following hemorrhagic shock exhibited a prolonged and amplified proinflammatory responses mediated by select interleukin, chemotactic, and glycoprotein cytokines that are not antagonized by anti-inflammatory mediators. This response is not related to randomization group, injury severity or degree of shock, but may be linked to adverse events.

Level of evidence: Prognostic, level III.

Trial registration: ClinicalTrials.gov NCT01545232.

PubMed Disclaimer

Conflict of interest statement

The authors do not have any conflicts of interest

Figures

Figure 1.
Figure 1.
Flow of Patients in the Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial
Figure 1.
Figure 1.
Time course of interleukin pro-inflammatory markers IL-6 (A) and IL-8 (B) in non-VTE (dark grey) and VTE (light grey) patients. *p<0.05 versus admission within group. †p<0.05 versus non-VTE for given time point.
Figure 2.
Figure 2.
Time course of cytokine markers G-CSF57 (A), MCP-1 (B), and MIP-1β (C) in non-VTE (dark grey) and VTE (light grey) patients. *p<0.05 versus admission within group. †p<0.05 versus non-VTE for given time point.
Figure 3.
Figure 3.
Time course of interleukin anti-inflammatory markers IL-1ra (A) and IL-10 (B) in VTE (dark grey) and VTE (light grey) patients. *p<0.05 versus admission within group. †p<0.05 versus non-VTE for given time point.
See this image and copyright information in PMC

References

    1. Van Haren RM, Valle EJ, Thorson CM, Jouria JM, Busko AM, Guarch GA, Namias N, Livingstone AS, Proctor KG. Hypercoagulability and other risk factors in trauma intensive care unit patients with venous thromboembolism. J Trauma Acute Care Surg. 2014;76(2):443–9. - PubMed
    1. Karcutskie CA, Meizoso JP, Ray JJ, Horkan D, Ruiz XD, Schulman CI, Namias N, Proctor KG. Association of Mechanism of Injury With Risk for Venous Thromboembolism After Trauma. JAMA Surg. 2017;152(1):35–40. - PubMed
    1. McLaughlin DF, Wade CE, Champion HR, Salinas J, Holcomb JB. Thromboembolic complications following trauma. Transfusion. 2009;49 Suppl 5:256S–63S. - PubMed
    1. Cotton BA, Minei KM, Radwan ZA, Matijevic N, Pivalizza E, Podbielski J, Wade CE, Kozar RA, Holcomb JB. Admission rapid thrombelastography predicts development of pulmonary embolism in trauma patients. J Trauma Acute Care Surg. 2012;72(6):1470–5; discussion 5-7. - PubMed
    1. Kashuk JL, Moore EE, Sabel A, Barnett C, Haenel J, Le T, Pezold M, Lawrence J, Biffl WL, Cothren CC, et al. Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery. 2009;146(4):764–72; discussion 72-4. - PubMed

Publication types

Associated data